Drug Type siRNA |
Synonyms CAS3/SS3 |
Target |
Mechanism STAT3 inhibitors(Signal transducer and activator of transcription 3 inhibitors), TLR9 antagonists(Toll like receptor 9 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
B-cell lymphoma recurrent | Phase 1 | - | 27 Jul 2021 | |
B-cell lymphoma refractory | Phase 1 | - | 27 Jul 2021 | |
Diffuse large B-cell lymphoma recurrent | Phase 1 | - | 27 Jul 2021 | |
Diffuse large B-cell lymphoma refractory | Phase 1 | - | 27 Jul 2021 | |
Mantle cell lymphoma recurrent | Phase 1 | - | 27 Jul 2021 | |
Mantle cell lymphoma refractory | Phase 1 | - | 27 Jul 2021 | |
Marginal zone lymphoma recurrent | Phase 1 | - | 27 Jul 2021 | |
Marginal zone lymphoma refractory | Phase 1 | - | 27 Jul 2021 | |
Recurrent Grade 3a Follicular Lymphoma | Phase 1 | - | 27 Jul 2021 | |
Recurrent Grade 3b Follicular Lymphoma | Phase 1 | - | 27 Jul 2021 |